Literature DB >> 22209769

Comparative morphological and immunohistochemical study of human meningioma after intracranial transplantation into nude mice.

Sabrina Friedrich1, Kerstin Schwabe, Rüdiger Klein, Claudia A Krusche, Joachim K Krauss, Makoto Nakamura.   

Abstract

Although surgical resection of benign human meningiomas is the primary goal, in case of relapse or when they are not fully resectable, other strategies including chemotherapeutical treatment would be appropriate. The initial evaluation of chemotherapeutical agents requires an appropriate tumor model, where the natural characteristics of the original benign tumor is reflected. We here tested, whether primary cell cultures of benign human meningiomas would reliably grow after intracranial transplantation into mice, and whether they would show histomorphological and immunohistochemical characteristics of the original human tumor. Cells of 11 benign human meningiomas were transplanted into the prefrontal cortex of nude mice. After 3 months, the mice were sacrificed and their brains were histologically processed for morphological characterization and measurement of tumor volume. Additionally, the proliferation index (PI), the microvessel density, and epithelial membrane antigen (EMA) were compared between human meningiomas and tumors grown in mice by using immunohistochemical methods. Further, cyclooxygenase-2 (COX-2) expression, a possible target for pharmacological manipulation, was examined. The results showed in almost all mice (93%) a tumor formation with meningothelial histomorphology comparable to the original human tumors. The PI, vascular density and COX-2 expression were similar between human and mice meningiomas, but EMA expression was reduced in mice (P<0.01). In conclusion an implantation of benign human meningioma primary cell cultures in mice reliably results in tumor formation with morphological and immunohistological features comparable to the original human tumor. This model may therefore be suitable to test novel therapeutic agents. Copyright Â
© 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22209769     DOI: 10.1016/j.jneumeth.2011.12.009

Source DB:  PubMed          Journal:  J Neurosci Methods        ISSN: 0165-0270            Impact factor:   2.390


  5 in total

Review 1.  Advances in meningioma genetics: novel therapeutic opportunities.

Authors:  Matthias Preusser; Priscilla K Brastianos; Christian Mawrin
Journal:  Nat Rev Neurol       Date:  2018-01-05       Impact factor: 42.937

2.  [Primary culture of human malignant meningioma cells and its intracranial orthotopic transplantation in nude mice].

Authors:  Mei-Xin Hu; Jia-le Liu; Xuan-Bo Chen; An-Qi Xu; Song-Ren Shu; Chao-Hu Wang; Yi Liu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-03-20

3.  Pleomorphism and drug resistant cancer stem cells are characteristic of aggressive primary meningioma cell lines.

Authors:  Ishaq Khan; Saleh Baeesa; Mohammed Bangash; Hans-Juergen Schulten; Fahad Alghamdi; Hanadi Qashqari; Nawal Madkhali; Angel Carracedo; Mohamad Saka; Awatif Jamal; Jaudah Al-Maghrabi; Mohammed AlQahtani; Saleh Al-Karim; Ghazi Damanhouri; Kulvinder Saini; Adeel Chaudhary; Adel Abuzenadah; Deema Hussein
Journal:  Cancer Cell Int       Date:  2017-07-21       Impact factor: 5.722

4.  Tumor-Derived Cell Culture Model for the Investigation of Meningioma Biology.

Authors:  Erik J Uhlmann; Rosalia Rabinovsky; Hemant Varma; Rachid El Fatimy; Ekkehard M Kasper; Justin M Moore; Rafael A Vega; Ajith J Thomas; Ronald L Alterman; Martina Stippler; Matthew P Anderson; Erik N Uhlmann; Franciela C Kipper; Anna M Krichevsky
Journal:  J Neuropathol Exp Neurol       Date:  2021-12-29       Impact factor: 3.685

5.  A new and reliable guide for studies of neuronal loss based on focal lesions and combinations of in vivo and in vitro approaches.

Authors:  Vera Paschon; Guilherme Shigueto Vilar Higa; Lais Takata Walter; Erica Sousa; Erica de Sousa; Fausto Colla Cortesão Zuzarte; Vivian Roca Schwendler Weber; Rodrigo Ribeiro Resende; Alexandre Hiroaki Kihara
Journal:  PLoS One       Date:  2013-04-09       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.